ATE384800T1 - Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten - Google Patents

Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten

Info

Publication number
ATE384800T1
ATE384800T1 AT01988344T AT01988344T ATE384800T1 AT E384800 T1 ATE384800 T1 AT E384800T1 AT 01988344 T AT01988344 T AT 01988344T AT 01988344 T AT01988344 T AT 01988344T AT E384800 T1 ATE384800 T1 AT E384800T1
Authority
AT
Austria
Prior art keywords
fusion proteins
treatment
protease
protease inhibitors
diseases
Prior art date
Application number
AT01988344T
Other languages
English (en)
Inventor
Philip Barr
Helen Gibson
Philip Pemberton
Original Assignee
Arriva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arriva Pharmaceuticals Inc filed Critical Arriva Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE384800T1 publication Critical patent/ATE384800T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01988344T 2000-12-18 2001-12-18 Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten ATE384800T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25669900P 2000-12-18 2000-12-18
US33196601P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
ATE384800T1 true ATE384800T1 (de) 2008-02-15

Family

ID=26945535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01988344T ATE384800T1 (de) 2000-12-18 2001-12-18 Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten

Country Status (7)

Country Link
EP (1) EP1366175B1 (de)
JP (2) JP4426179B2 (de)
AT (1) ATE384800T1 (de)
AU (2) AU2002241661B2 (de)
CA (1) CA2430973A1 (de)
DE (1) DE60132632T2 (de)
WO (1) WO2002050287A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052236A2 (en) * 2002-12-06 2004-06-24 Arriva Pharmaceuticals, Inc. Methods and compositions for treatment of otitis media
US20070098635A1 (en) * 2003-04-08 2007-05-03 Genova Ltd. Secreted polypeptide species associatedwith cardiovascular disorders
AU2004263900A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
SE0302559D0 (sv) * 2003-09-25 2003-09-25 Astrazeneca Ab Method
US7914771B2 (en) 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
JP2007037434A (ja) * 2005-08-02 2007-02-15 Yamaguchi Univ 膵β細胞特異的に発現される人工タンパク質、該タンパク質をコードしたレポーター遺伝子及び膵β細胞量の計測方法
EP2012819A2 (de) 2006-03-30 2009-01-14 The Research Foundation Of the City university of New York Stimulation der regeneration von nervenzellen durch einen sekretleukozyten-proteasehemmer
US8802627B2 (en) 2008-10-09 2014-08-12 Oriental Yeast Co., Ltd. Fusion protein composed of matrix metalloproteinase-2 inhibitor peptide derived from amyloid-B precursor protein and tissue inhibitor of metalloproteinase-2
CA2808675A1 (en) * 2010-09-14 2012-03-22 F. Hoffmann-La Roche Ag Serpin-finger fusion polypeptide
SMT201900520T1 (it) * 2011-06-28 2019-11-13 Inhibrx Lp Polipeptidi di fusione serpinici e relativi metodi d'uso
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
BR112014007127A2 (pt) 2011-12-30 2017-04-04 Grifols Sa métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit
JP6436401B2 (ja) * 2013-04-30 2018-12-12 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 弾性繊維損傷マーカーの解析
CN105745223A (zh) 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
AU2014324093A1 (en) * 2013-09-18 2016-04-28 James Cook University Anti-inflammatory proteins and methods of use
IT202000012370A1 (it) * 2020-05-26 2021-11-26 Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L Composizione comprendente pepstatina e acido alginico o un suo sale e suo uso
US20230414730A1 (en) * 2020-11-06 2023-12-28 Aatec Medical Gmbh A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
DE3709255A1 (de) * 1987-03-20 1988-09-29 Hoechst Ag Hybridserpine und dafuer kodierende dna
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
JP2001525669A (ja) * 1997-05-12 2001-12-11 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 細胞遊走の阻害のための方法および構築物
EP1231936A2 (de) * 1999-10-27 2002-08-21 K-Quay Enterprises, LLC Verfahren und zusammensetzungen für behandlung von keratokonus mit proteaseinhibitoren

Also Published As

Publication number Publication date
CA2430973A1 (en) 2002-06-27
EP1366175B1 (de) 2008-01-23
WO2002050287A2 (en) 2002-06-27
EP1366175A2 (de) 2003-12-03
JP2004537970A (ja) 2004-12-24
JP2009297031A (ja) 2009-12-24
AU2002241661B2 (en) 2007-05-31
DE60132632D1 (de) 2008-03-13
DE60132632T2 (de) 2009-01-22
WO2002050287A3 (en) 2003-09-18
JP4426179B2 (ja) 2010-03-03
AU4166102A (en) 2002-07-01

Similar Documents

Publication Publication Date Title
DE60132632D1 (de) Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten
Amour et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs
Moss et al. Shedding of membrane proteins by ADAM family proteases
NO923469L (no) Chymotrypsin-lignende proteaser og deres inhibitorer
HUP9902698A2 (hu) Humán bikunin
DE60128916D1 (de) Neues, physiologisch aktives peptid und dessen verwendung
ATE266723T1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE69132352D1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
DE60218179D1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
ATE108205T1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
WO1996035788A3 (en) Kunitz type protease inhibitors
DE602005023133D1 (de) Prozess und reagenzien für extraktion von rns von fraktionierten blutleukozyten
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
WO2002010357A3 (en) Gsk3 polypeptides
DK0458937T3 (da) Varianter af PAI-2
Konttinen et al. Substrate specificity and activation mechanisms of collagenase from human rheumatoid synovium
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
ATE510911T1 (de) Prothrombin aktivierendes protein
ATE251904T1 (de) Verwendung von bronopol zur behandlung von krankheiten beim fisch
ATE452984T1 (de) Verfahren und zusammensetzungen zur extraktion von proteinen aus zellen
DE60123109D1 (de) Mit schizophrenie in zusammenhang stehendes gen, das für ein potential-abhängiges ionkanal kodiert

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties